Enoby Injection
Product Images NDC 0143-9165

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Enoby (NDC 0143-9165). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Enoby Before Use (Enoby Denosumab Qbde Injection 1)

An instructional illustration showing the labeled parts of a pre-use syringe for ENOBY (Denosumab-qbde) 60 mg/mL injection. The diagram identifies the plunger, finger grips, syringe label, syringe barrel, syringe safety guard, needle safety spring, and a grey needle cap on the syringe tip.*

FDA Label Image

Enoby After Use (Enoby Denosumab Qbde Injection 2)

An instructional diagram showing a labeled cross-section of a used syringe after injection. It identifies the parts as used plunger, syringe label, used syringe barrel, used needle, and used needle safety spring with a separate insert showing the grey needle cap removed.*

FDA Label Image

Enoby Figure A (Enoby Denosumab Qbde Injection 3)

An instructional illustration showing hands preparing a syringe for injection by removing the cap from the needle in an upward direction. The image is related to the subcutaneous injection process for the drug ENOBY (Denosumab-qbde) 60 mg/mL, produced by Hikma Pharmaceuticals USA Inc.*

FDA Label Image

Enoby (Figure B)

An instructional anatomical illustration showing three recommended subcutaneous injection sites on a human figure: the upper arm, abdomen, and upper thigh. Each area is highlighted to indicate appropriate injection locations for the medication.*

FDA Label Image

Enoby Figure D (Enoby Denosumab Qbde Injection 5)

An instructional illustration showing a hand administering a subcutaneous injection with a prefilled syringe. An arrow labeled 'SNAP' indicates the action of snapping or removing a cap or cover from the needle before injection into the skin, demonstrating a step in the injection procedure.*

FDA Label Image

Enoby Figure E (Enoby Denosumab Qbde Injection 6)

An illustration showing a hand holding a prefilled injection device, positioned for subcutaneous injection into the skin of an arm. The image includes an arrow indicating the direction to pull or activate the device for administering injection, consistent with instructions for subcutaneous use.*

FDA Label Image

Figure-1 (Enoby Denosumab Qbde Injection 7)

A line graph comparing patient hip fracture incidence (%) over a 36-month study period between two groups: placebo (dashed line, N=3906) and denosumab (solid line, N=3902). The graph shows lower hip fracture incidence in the denosumab group throughout the study months.*

FDA Label Image

Enoby_label (Enoby Denosumab Qbde Injection 8)

Label for ENOBY (denosumab-qbde) injection 60 mg/mL, a subcutaneous injection by Hikma Pharmaceuticals USA Inc. The label indicates this is a single-dose prefilled syringe, with instructions to discard unused portions. It includes the product NDC 0143-9165-01 and license details, along with a barcode and usage warnings.*

FDA Label Image

Enoby_carton (Enoby Denosumab Qbde Injection 9)

Packaging label for Enoby (denosumab-qbde) Injection, 60 mg/mL, a subcutaneous injection by Hikma Pharmaceuticals USA Inc. The label includes dosage strength, dosage form, storage instructions, and manufacturer details, with emphasis on single-dose prefilled syringe usage and refrigeration requirements. The label features the Hikma logo and NDC 0143-9165-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.